{"schema_version":"secwatch.filing_event.v1","accession":"0001625297-25-000064","form_type":"8-K/A","ticker":"INDV","cik":"0001625297","company_name":"Indivior Pharmaceuticals, Inc.","filed_at":"2025-10-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.965234+00:00","generated_at":"2026-05-17T01:21:06.053978+00:00","sec_items":["2.05"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"confidence":"high","headline":"Indivior estimates $105-130M restructuring charges; exits six non-US markets","bullets":["Total pre-tax restructuring charges estimated at $105-130M, with $65M recognized in Q3 2025.","Plans to exit markets: UK, Ireland, Sweden, Israel, Finland, Italy under Action Agenda Phase I.","Expects at least $150M annual operating expense savings starting in 2026.","Cash portion of charges $73-92M; includes severance, real estate, asset impairments, contract terminations.","Headcount reductions cost $33-37M; real estate consolidation $15-21M; asset impairments $21-27M."],"urls":{"canonical":"https://secwatch.observer/filing/0001625297-25-000064","json":"https://secwatch.observer/filing/0001625297-25-000064.json","markdown":"https://secwatch.observer/filing/0001625297-25-000064.md","text":"https://secwatch.observer/filing/0001625297-25-000064.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1625297/000162529725000064/0001625297-25-000064-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1625297/000162529725000064/indv-20250826.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T01:21:06.053978+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}